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Background: Over-proliferation of airway smooth muscle cell (ASMC) is one of the important contributors to airway
remodeling in asthma. The aim of this study was to investigate the effect of Shenmai injection (SMI) on the
proliferation of the rat ASMC in asthma.
Methods: Rats were randomly divided into three groups: the control group, the asthma group, and the SMI
treatment group. Reverse transcription-polymerase chain reaction (RT-PCR) and immunocytochemistry staining were
used to detect the mRNA and protein expression of transient receptor potential vanilloid 1 (TRPV1) and proliferating
cell nuclear antigen (PCNA) in rat ASMC respectively. Intracellular Ca2+ concentration ( [Ca2+]i ) in rat ASMC were
measured with Fluo-3/AM by confocal microscopy. The proliferation was detected by MTT assay.
Results: Compared with the control group, the asthma group showed an increased expression of TRPV1 and [Ca2+]
i in rat ASMC. The expression of PCNA and absorbance of MTT assay in asthma rat ASMC was also significantly
increased. SMI could significantly decrease the expression of TRPV1 channel and [Ca2+]i in the asthmatic rat ASMC.
Furthermore, the expression of PCNA and absorbance of MTT assay in asthmatic rat ASMC was significantly reduced
after SMI treatment.
Conclusions: SMI may prevent asthma-induced ASMC over-proliferation probably by inhibiting the expression of
TRPV1 channel, which regulates the intracellular calcium concentration.
Keywords: Shenmai injection (SMI), Transient receptor potential vanilloid 1 (TRPV1), Airway smooth muscle cells
(ASMC), Intracellular calcium, Airway remodelingBackground
Bronchial asthma is a highly prevalent chronic respira-
tory disease that is seriously hazardous to human health.
Because the pathogenesis of asthma has not been clearly
identified, only symptom control can be achieved with
the current treatment. Therefore, further clarification of
the pathogenesis of asthma and searching for more
effective treatments are the hot topics of research at
present. Airway remodeling is an important pathological
feature of asthma and is the pathological basis of irre-
versible airflow obstruction [1-3]. An increase of airway
smooth muscle (ASM) mass due to proliferation and
hypertrophy of ASM cells (ASMC) plays an important* Correspondence: malijun0401@163.com
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reproduction in any medium, provided the orrole in the pathophysiology of airway hyper-responsive-
ness and remodeling in asthma [4,5].
Calcium is an important second messenger in ASMC.
Intracellular Ca2+ has been shown to regulate cell prolif-
eration, differentiation, signal transduction, and so on
[6-8]. The transient receptor potential vanilloid receptor
(TRPV) is an important Ca2+ signaling pathway, espe-
cially for TRPV1 channel [9]. It has been reported that
the loss of function of TRPV1 genetic variant is associ-
ated with lower risk in active childhood asthma, with the
reason of intracellular Ca2+ dysregulation induced by
TRPV1 channel [10].
Shenai injection (SMI) is extracted from red ginseng
and ophiopogon root. According to traditional Chinese
medicine theory, SMI benefits qi, prevents exhaustion,
nourishes yin, and replenishes bodily fluids with thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and




Figure 1 The bronchial smooth muscle of each group
(HE staining). The thickness of ASM in chronic asthma rats was
significantly increased. After SMI treatment, the over-proliferation of
ASM was significantly inhibited. Bar = 20 μm.
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widely used for clinical treatment of qi-yin deficiency in
coronary heart disease, chronic pulmonary heart disease,
viral myocarditis, heart and respiratory failure, cerebral
infarction and malignant diseases [12]. Our previous
studies had found that SMI was demonstrated, in a
dose-dependent manner, to inhibit the extracellular sig-
nal regulated kinase (ERK) transduction pathway and
the proliferation of human ASMC, preventing airway re-
modeling to occur [13]. SMI could significantly down-
regulate the activity of Ca2+ channel protein in asthmatic
rat models and could possibly exhibit a preventive and
therapeutic effect on asthma [14]. SMI showed a definite
effect on the Fas and FasL protein expression and
inhibited diaphragmatic muscle cell apoptosis, explai-
ning its therapeutic effect on diaphragmatic fatigue
caused by hypoxia [15]. However, there had no report on
the effect of SMI on ASMC proliferation in asthma and
its underlying mechanism. Therefore, this study was
designed to investigate the effects of SMI on ASMC pro-
liferation, the expression and activity of TRPV1 channel
in asthma, with an objective to understand how SMI af-
fects TRPV1 channel-induced ASMC over-proliferation
in asthma.
Methods
Establishment of rats chronic asthmatic model and
grouping
30 male Sprague–Dawley rats (6 weeks old, 180-200 g
body weight) were randomly divided into 3 groups: the
control group, the asthmatic group, and the SMI treat-
ment group. Each group consisted of 10 rats. The rats
were kept in SPF animal research facilities under stand-
ard laboratory conditions and received food and water
ad libitum. All experimental procedures were carried out
in accordance with the NIH Guidelines for the Care and
Use of Laboratory Animals and were approved by
Chinese Institute of Oriental Medicine Institutional
Animal Care and Use Committee. The animals were
cared for in accordance with the National Animal
Welfare and Protection Law of China.
The modified protocols for rats sensitization and chal-
lenge were used as reported previously [16]. Rats were
actively sensitized with subcutaneous injection of 10 mg
ovalbumin (OVA, Sigma, USA.) together with 200 mg
aluminum hydroxide (Sigma, USA) in 1 ml 0.9% NaCl
solution, and 1 ml inactivated bordetella pertussis vac-
cine (6 × 109 heat-killed baciUin, Chengdu Institute of
Biological Product, China) was administered intraperi-
toneally on the first day (Day 1). The rats were sensi-
tized again on the eighth day (Day 8). Then the next
six weeks the rats were exposed to aerosolized 2%
OVA in 0.9%NaCl, which was generated by an ultra-
sonic nebulizer with 3 ml/min output, for 30 minutesand repeated three times a week. The total experimen-
tal time was eight weeks. After challenged, the rats
showed symptoms of asthmatic attack such as agita-
tion, bucking, tachypnea, cyanosis, and so on. In con-
trol group, the rats were sensitized and challenged with
the same volume of 0.9% NaCl instead of OVA. In SMI
treatment group, the rats were not only sensitized and
challenged by OVA to make the chronic asthmatic
model, but also injected intraperitoneally with 2 mL
SMI every day. The effective dose of SMI was deter-
mined by our previous studies [15,17]. The rats were
sacrificed within 18–24 hours after the final challenge
in each group.
Table 1 Comparison of WA/Pi, S/Pi, N/Pi of each group ((x–±s,n=10)
Group WA/Pi (μm2/μm) S/Pi (μm2/μm) N/Pi (n/μm)
Control group 7.02 ± 0.31 2.57 ± 0.24 0.0181 ± 0.0042
Chronic asthma group 11.82 ± 1.37** 3.71 ± 0.47** 0.0388 ± 0.0162*
SMI group 7.74 ± 0.29# # 2.68 ± 0.34# 0.0184 ± 0.0056#
F 63.245 17.923 8.136
P <0.001 0.005 0.029
*P < 0.05, **P < 0.01 vs. the control group.
#P < 0.05, # #P < 0.01 vs. the chronic asthma group.
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Lung tissue sections stained with Hematoxylin and Eosin
(HE) in each group were selected and analyzed with
422BLK8079 High-resolution Medical Colorful Image
Analyzing System (Yiming Technology Development
Co., Ltd., Guangzhou, China). The airway internal per-
imeter (Pi), wall area (WA), the area of bronchial
smooth muscle (S) and the number of bronchial smooth
muscle nucleus (N) were measured. Then the above
measured values were standardized by Pi and WA/Pi,
S/Pi, N/Pi represented respectively.A
C
Figure 2 Primary rat ASMC. A: Cells growing around the tissues with spin
confluence occurring in 8-10 days (phase-contrast microscopy). Bar = 100 μ
Bar = 50 μm. C: Positive α-actin fluorescent immunostaining with green parASMC isolation, culture and identification
ASMC were cultured using the reported method with
some improvement [18]. Male rats were deeply anesthe-
tized with pentobarbital sodium (5 ml/kg ip) and
euthanized by exsanguination according to the protocol
approved by the Institutional Animal Care and Use
Committees of Zhengzhou University, China. Large
bronchi which dissected from the surrounding paren-
chyma were washed three times in precooled modified
Krebs-Henseleit solution [(in mM): 118 NaCl, 4.7 KCl,
1.2 NaH2PO4, 25.5 NaHCO3, pH value adjusted to 7.4B
dle-shaped, cell body and central oval nuclei in 2–3 days, then cells
m. B: Typical “hill and valley” appearance in ASMC (HE staining).




































Figure 3 The mRNA expression of TRPV1 and PCNA in ASMC of
each group. (A) RT-PCR of TRPV1, PCNA and β-actin in rat ASMC of
each group. 1. Control group; 2. Asthma group; 3. SMI group.
(B) Summary of mRNA expression of TRPV1 and PCNA in ASMC of
each group (n = 8). The relative values of A of TRPV1 and PCNA
were normalized to β-actin. **P < 0.01 vs. the control group.
# #P < 0.01 vs. the asthma group.
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100 U/ml and streptomycin 100 U/ml). Airways without
cartilages were selected and pure airway smooth muscle
bundles were cut free from surrounding tissues with the
aid of a dissecting microscope. Then the airway was cut
open and the endothelium was disrupted by gently strip-
ping the luminal surface with a blade. The minced tissue
(1 mm3 fragments) were seeded into sterilized 25 ml cul-
ture flasks and 2-3 ml DMEM (Gibco, USA) containing
20% (v/v) fetal bovine serum (FBS, Gibco, USA) and 100
U/ml penicillin G and streptomycin was added. The
flasks were placed in a 5% CO2 humidified incubator
at 37°C. The culture medium was replaced regularly
(2-3 days) until cell confluence occurred (usually 8-10
days). Then the cells were digested with 0.25% trypsin
(containing 0.02% EDTA, Gibco, USA) and subcultured
in DMEM with 10% FBS. Immunofluorescence staining
for α-smooth muscle actin (α-actin) was used to identify
the smooth muscle cells. Cells were used for experiment
between passages 3 and 5.
RT-PCR to detect the mRNA expression of TRPV1 channel
and PCNA
RNA was isolated and purified using Trizol regent
(Gibco, USA) according to the manufacturer’s instruc-
tions. cDNA was synthesized from mRNA with the aid
of an omniscript reverse transcriptase (Qiagen, CA)
using 100 ng of RNA per reaction. PCR amplification
(40 cycles of 95°C for 30 s, 55°C for 30 s, 68°C for
1 min; 72°C for 5 min) was performed with 5 μl of cDNA
using the specific TRPV1 primer (Qiagen QT00180782),
PCNA primer (Qiagen QT00178647) and β-actin (Qiagen
QT00193473), yielding a product of 104 bp, 93 bp
and 145 bp respectively. The amplified PCR products
were confirmed by electrophoresis on 1.5% agarose gel
containing ethidium bromide. The straps of amplified
products were analyzed with MUVB-20 gel analysis sys-
tem (Ultralum Corporation, USA) and the absorbance
value (value of A) of each strap was measured. The rela-
tive values of A of TRPV1 and PCNA were normalized to
β-actin.
Immunofluorescence staining to detect the protein
expression of α-actin and TRPV1
Immunocytochemistry was used to study the expression
of α-actin and TRPV1 proteins in primary rat ASMC.
ASMC were fixed with 4% formaldehyde for 10 minutes,
permeabilized with methanol (−80°C), blocked with 2%
bovine serum albumin (in phosphate buffered saline),
and incubated with a primary sheep monoclonal anti-
body specific to α-actin and rabbit monoclonal antibody
specific to TRPV1(1:100, Santa Cruz Biotechnology Inc.,
USA) overnight at 4°C. Cells were washed and incubated
with a 1:500 fluorescent anti-sheep secondary antibodyconjugated with a FITC fluorophore (green fluorescence,
Santa Cruz Biotechnology Inc., USA) for α-actin detec-
tion and anti-rabbit conjugated with Texas (red fluores-
cence, Santa Cruz Biotechnology Inc., USA) for TRPV1
detection for two hours at room temperature in the
dark. Cell nuclei were counterstained with 4′,6-diami-
dino-2-phenylindole (DAPI, blue fluorescence, Santa
Cruz Biotechnology Inc., USA). The fluorescence images
for immunocytochemistry were obtained using a laser-
scanning confocal microscope (Olympus). The excitation
of FITC was by illumination at 488 nm, 561 nm for
Texas and 405 nm for DAPI. For the measurement of
TRPV1 channel expression, the mean fluorescence in-
tensity was quantified using the Olympus micro-image
4.0 analyzing software (Japan). The mean fluorescence
intensity was normalized to the control group.
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( [Ca2+]i )
The [Ca2+]i was measured using the intracellular calcium
indicator Fluo-3/AM (Invitrogen, USA). The ASMC were
loaded with 5 μM Fluo-3/AM for 30 minutes at 37°C in
the dark. After they were washed with physiological HEPES
buffered solution (in mM): 146 NaCl, 4.7 KCl, 2.5 CaCl2,
0.6 MgSO4, 0.15 NaHPO4, 0.1 ascorbic acid, 8 glucose and
10 HEPES; (pH 7.4), the cells were viewed using a confocal
microscope (400× oil immersion objective, Olympus,
Japan). Fluo-3/AM fluorescence was excited at 488 nm
and emitted at 510/530 nm. [Ca2+]i was calculated using
the formula: [Ca2 +]i = Kd[F ‐ Fmin]/[Fmax ‐ F], where the
Kd for Fluo-3/AM is 400nM, F is the actual fluorescence
intensity of the cell, Fmin is the fluorescence intensity
when the cell was treated with 3 mM EGTA (Sigma,






















Figure 4 Expression of TRPV1 protein in rat ASMC of each group. Rep
ASMC of control group (A), chronic asthma group (B) and SMI group (C). T
cytoplasm.Nuclei were dyed with blue. Bar = 10 μm. D. Summarized data o
fluorescence intensity of control group was set to 1.0. The mean fluorescen
**P < 0.01 vs. the control group. # #P < 0.01 vs. the asthma group.was incubated with HEPES buffered solution containing
10 mM CaCl2.
Detection of PCNA by immunocytochemistry
Streptavidin-perosidase (SP) method was used for PCNA
immunohistochemical staining. Operate according to SP
kit instructions. Diluted concentration of mouse
monoclonal antibody specific to PCNA (Santa Cruz
Biotechnology Inc., USA) was 1:100. Colored with
diaminobenzidine (DAB, Gibco, USA). The positive
staining of PCNA was brown color, mainly located in
the nucleus. Randomly select five views of each cell
coverslip, measure and analyze the optical density (value
of OD), then calculate the average value of OD of each
group. Set the relative value of OD of the control group
as 1.0, and the relative value of OD of the other two




resentative images of immunofluorescent labeling for TRPV1 in rat
he positive staining of TRPV1 was red fluorescence in membrane and
f TRPV1 protein expression in ASMC of each group. The mean
ce intensity of the other two groups was normalized to control group.
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bromide (MTT) assay to detect the cell proliferation
Rat ASMC were digested with 0.25% trypsin-EDTA and
then seeded into 96-well culture plate with the density
of 1 × 104/ml. After two days, 12 mM MTT stock solu-
tion (Gibco, USA) was added to each well. Incubate at
37°C for 4 hours. Remove the entire medium from the
wells, add 150 μL of dimethyl sulfoxide (DMSO, Sigma,
USA) to dissolve the colored formazan crystals, and mix
thoroughly with the oscillator for 10 minutes. Then read
absorbance at 490 nm wavelength (value of A490) with
an enzyme-linked immunosorbent assay reader (Bio-tek
ELX800, USA). The value of A490 is proportional to the





















Figure 5 Intracellular Ca2+ concentration ([Ca2+]i) in rat ASMC of each
ASMC of each group. ASMC were incubated with Fluo-3/AM, so the green
asthmatic ASMC was increased compared with the control group, and SMI
zed data showed that TRPV1 selective agonist capsaicin increased [Ca2+]i a
were significantly increased and [Ca2+]i was reduced down to the normal l
# #P < 0.01 vs. the blank control group (B).Statistical analysis
All data were expressed as mean ± SD x  sð Þ . SPSS 16.0
software was used for statistical analysis. Differences
among several groups were determined with the One-way
ANOVA. Differences were considered significant with P <
0.05. Sigma Plot v11.0 was used to compile the figures.Results
Pathomorphological image of airway remodeling
In chronic asthmatic rats, the mucosal fold membranes
of bronchiole were increased and broken. A large num-
ber of eosinophils infiltrated into the bronchial sub-
mucosa and the thickness of airway wall and bronchialBlank
Capsaicin
Capsazepine






group. Representative images of intracellular Ca2+ fluorescence in
fluorescences were observed in the cells. The fluorescence intensity in
could diminish the fluorescence intensity. Bar =10 μm (A). Summari-
nd inhibitor capsazepine decreased [Ca2+]i. [Ca
2+]i of asthmatic ASMC
evel in SMI group (n = 20). *P < 0.05, **P < 0.01 vs. the blank group .
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airway remodeling was formed in the chronic asthmatic
model. But after SMI treatment, airway remodeling was
significantly reduced (Figure 1). WA/Pi, S/Pi, N/Pi of
each group were shown in Table 1.
Characteristics and identification of rat ASMC in primary
culture
In phase-contrast imaging, cells cultured for 2–3 days
from airway appeared to be spindle-shaped and had cen-
tral oval nuclei with prominent multiple nucleolus. In
8–10 days, the cells began to merge and displayed the
typical “hill and valley” appearance of smooth muscle
cells (Figure 2A and B). α-actin was detected by im-
munofluorescence staining and appeared positively as
green parallel fiber in cytoplasm (Figure 2C).
Expression of TRPV1 in ASMC of each group
The mRNA expression of TRPV1 in asthmatic rat
























Figure 6 Expression of PCNA in rat ASMC of each group. Representativ
control group (A), chronic asthma group (B) and SMI group (C). The positi
Bar = 100 μm. D. Summarized data of PCNA protein expression of ASMC of
and the relative value of OD of other two groups was normalized to the co
asthma group.group [the value A from (1.04 ± 0.14) to ÿ1.87 ± 0.41,
P < 0.01]. And after SMI treatment, the expression of
TRPV1 in asthmatic rat ASMC (0.98 ± 0.13) was signifi-
cantly decreased (P < 0.01) (Figure 3A,B).
TRPV1 protein was detected by immunofluorescence
labeling. The red fluorescence signals were observed with
a fluorescent confocal microscope (Figure 4A,B and C).
As shown in Figure 4D, the protein expression of TRPV1
in asthmatic rat ASMC was significantly increased [the
value A from (0.98 ± 0.12) to ÿ1.90 ± 0.57), P < 0.01]. In
the SMI treatment group, the protein expression of
TRPV1 channel (1.03 ± 0.14) was significantly decreased
in ASMC (P < 0.01).
The result showed that SMI significantly inhibited the
expression of TRPV1 channel.
[Ca2+]i in ASMC
ASMC were incubated with Fluo-3/AM, so the green
fluorescences were observed in the cells. The fluores-




e images of immunocytochemistry for PCNA in rat ASMCs of
ve staining of PCNA was brown color, mainly located in the nucleus.
each group. Set the relative value of OD of the control group as 1.0,
ntrol group. **P < 0.01 vs. the control group. # #P < 0.01 vs. the
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ish the fluorescence intensity (Figure 5A). TRPV1 select-
ive agonist capsaicin increased [Ca2+]i and inhibitor
capsazepine decreased [Ca2+]i. So TRPV1 channel was
involved in regulating [Ca2+]i of ASMC. [Ca
2+]i of asth-
matic ASMC were significantly increased and [Ca2+]i
was reduced down to the normal level in SMI group
(n = 20). Therefore SMI reduced the [Ca2+]i in asthmatic
rat ASMC (Figure 5B).
SMI inhibited the proliferation of asthmatic rat ASMC
Immunostaining, ×400
Expression of PCNA in ASMC of each group
As shown in Figure 3 and Figure 6, the mRNA and pro-
tein expression of PCNA in asthmatic rat ASMC were
significantly increased compared with the control group.
Whereas SMI could inhibit the increase of PCNA ex-
pression induced by asthma (P < 0.01).
The results of MTT assay
The value of A490 of each group was shown in Table 2.
The value A490 of asthma group was significantly in-
creased. After SMI treatment, the value A490 was de-
creased. That meant that SMI could inhibit the ASMC
over-proliferation caused by asthma ( P <0.05).
Discussion
Asthma is a common chronic inflammatory respiratory
disease over the globe, linking to 250, 000 cases of
deaths each year [19]. It is characterized by airway in-
flammation, airway wall remodeling and airway hyper-
responsiveness (AHR). Moreover, airway wall remodeling
can lead to airway inflammation and AHR [20]. As a
characteristic of pathological change in asthma; airway
remodeling was also the pathological basis of chronic,
persistent, severe, steroid-resistant asthma, and irrevers-
ible airway obstruction [21-24].
Airway remodeling refers to structural changes such as
bronchial fibrosis, increase in basal membrane thickness,
smooth muscle hyperplasia and hypertrophy and so on
[25]. In particular, smooth muscle remodeling has been
associated with a decrease in lung function leading to aTable 2 MTT absorbance of each group (x–±s, n=10)
Group Well Value of A490
Control group 6 0.296 ± 0.024
Chronic asthma group 6 0.535 ± 0.087*
SMI group 6 0.312 ± 0.036#
F 33.912
P 0.001
*P < 0.05 vs. the control group.
#P < 0.05 vs. the chronic asthma group.more severe asthma phenotype [21,26]. Therefore, study-
ing the mechanism of ASMC proliferation is essential in
asthma research.
The transient receptor potential ion channel protein
(TRP) is a class of transient non-selective receptor pro-
teins for Ca2+ cations present in cell membranes or
intracellular organelle membranes. The TPR family in-
cludes seven sub-families: TRPC, TRPV, TRPM, TRPML,
TRPP, TRPA and TRPN channels. In particular, TRPV is
a major sub-family with at least six known members in
mammals, namely TRPV1-6 [27,28]. Among them,
TRPV1 channel is the first cloned [29], more studied
and more popular channel. Therefore in this study, we
focused on the TRPV1 channel in ASMC.
The TRPV1 channel is presented in various parts of
the mammalian respiratory system, including the trachea
sensory nerves, ASMC, epithelial cells, pulmonary vas-
cular endothelial cells, pulmonary artery smooth muscle
cells, sub-mucosal glands, and inflammatory cells [30].
In recent years, studies showed that TRPV1 channel
played a crucial role in the cough reflex. When the TRPV1
channel was activated, which induced Ca2+ influx into
the nerve cells, causing membrane depolarization to
reach the threshold potential, which in turns led to bron-
choconstriction, mucus secretion and the cough reflex
[31]. In addition, the Ca2+ influx caused by TRPV1 channel
activation could trigger the release of tachykinin (TK)
and calcitonin gene-related peptide (CGRP) in periph-
eral and central nervous system, resulting in brocho-
constriction, protein secretion, tracheal mucosal edema
and inflammatory cell chemokines [32]. Cantero’s re-
port [10] showed that TRPV1 channel was highly rele-
vant to asthma because the level and activity of the
genetic determinants of TRPV1 channel affected the oc-
currence and pathophysiological processes of asthma. In
another study, it was found that chronic hypoxia signifi-
cantly increased the mRNA and protein expression of
TRPV1 channel in human pulmonary artery smooth
muscle cells, leading to an increase in cytosolic Ca2+ con-
centration and thus cell over-proliferation [33]. However,
the role of TRPV1 channel in ASMC proliferation of
asthma has not been reported.
For that reason, we have studied the TRPV1 channel
in rat ASMC and found that the TRPV1 channel was
one of the important channels to regulate calcium influx
in rat ASMC. The TRPV1 expression was observed to
increase in the asthmatic rat ASMC, leading to an in-
crease in the intracellular calcium concentration, which
in turn resulted in an increase of the expression of
PCNA. PCNA was chosen as a marker for proliferation.
The PCNA expression could reflect the state of cell pro-
liferation. When the PCNA expression was increased,
cell proliferation was promoted. Conversely, cell prolifer-
ation would be inhibited when the PCNA expression
Zhao et al. BMC Complementary and Alternative Medicine 2013, 13:221 Page 9 of 10
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excessive proliferation and thus asthma-induced airway
remodeling occurred.
As the understanding of SMI deepens, more and more
attention has been given to the clinical applications of
SMI in the treatment of respiratory system diseases. SMI
has been widely used in the treatment of chronic ob-
structive pulmonary disease (COPD), asthma, pulmonary
heart disease [12], lung cancer patients [35] and so on.
This study found that SMI could down-regulate the
expression of TRPV1 channel from an abnormally high
level to almost normal level in asthmatic rat ASMC. At
the same time the level of intracellular calcium and the
expression of PCNA also returned to normal in these
ASMC. Therefore, the over-proliferation of ASMC
caused by asthma was inhibited by SMI.
Conclusions
In summary, these findings suggest that SMI may effect-
ively inhibit the progression of asthma-induced ASMC
remodeling. This anti-remodeling effects of SMI were
probably mediated partially by downregulation of TRPV1
channel. Although clinical applications require further in-
vestigation, this study has provided the scientific experi-
mental basis for SMI to prevent and treat the airway
remodeling in asthma.
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